These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17205515)

  • 21. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).
    Comella P; Filippelli G; De Cataldis G; Massidda B; Frasci G; Maiorino L; Putzu C; Mancarella S; Palmeri S; Cioffi R; Roselli M; Buzzi F; Milia V; Gambardella A; Natale D; Bianco M; Ghiani M; Masullo P;
    Ann Oncol; 2007 Feb; 18(2):324-30. PubMed ID: 17071935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.
    Bokobza SM; Jiang Y; Weber AM; Devery AM; Ryan AJ
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):947-54. PubMed ID: 24606853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
    Zhang W; Zhang W; Wang L; Zheng J; Xiao F
    Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):385-90. PubMed ID: 21569641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
    Lord RV; Brabender J; Gandara D; Alberola V; Camps C; Domine M; Cardenal F; Sánchez JM; Gumerlock PH; Tarón M; Sánchez JJ; Danenberg KD; Danenberg PV; Rosell R
    Clin Cancer Res; 2002 Jul; 8(7):2286-91. PubMed ID: 12114432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
    Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
    Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
    Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
    Dal Bello MG; Alama A; Barletta G; Coco S; Truini A; Vanni I; Boccardo S; Genova C; Rijavec E; Biello F; Bottoni G; Sambuceti G; Grossi F
    Int J Cancer; 2015 Dec; 137(12):2947-58. PubMed ID: 26089022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
    Shimizu J; Horio Y; Mitsudomi T
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1879-85. PubMed ID: 16282720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
    Bokobza SM; Jiang Y; Weber AM; Devery AM; Ryan AJ
    Oncotarget; 2014 Jul; 5(13):4765-78. PubMed ID: 24946858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
    Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
    Ihle NT; Paine-Murrieta G; Berggren MI; Baker A; Tate WR; Wipf P; Abraham RT; Kirkpatrick DL; Powis G
    Mol Cancer Ther; 2005 Sep; 4(9):1349-57. PubMed ID: 16170026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
    Ohta T; Ohmichi M; Shibuya T; Takahashi T; Tsutsumi S; Takahashi K; Kurachi H
    Cancer Biol Ther; 2012 Apr; 13(6):408-16. PubMed ID: 22313686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways.
    Liu Z; Fu Q; Wang Y; Cui L; Zhang W; Teng Y; Yu P
    Biomed Pharmacother; 2021 Feb; 134():111144. PubMed ID: 33360044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine.
    De Pas T; de Braud F; Mandalà M; Curigliano G; Catania C; Ferretti G; Sozzi P; Solli P; Goldhirsch A
    Lung Cancer; 2001; 31(2-3):267-70. PubMed ID: 11165406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N; Zhang Q; Fang S; Han X; Wang Z
    Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.